SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Trinity Biotech (TRIBY)
TRIB 0.690-2.8%Jan 16 9:30 AM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: DMore who wrote (8398)3/6/1998 9:28:00 AM
From: Scott H. Davis  Read Replies (2) of 14328
 
DMore & All: There is the potential for > 30% annual growth in EPS if revenues grow 30% since margins would improve (assuming SG&A expenses stay in line), but you're adding 30% qtrly, not annually. Brendan was not comfortable with the .15 projection for this year, so .189 appears to be really streatching it.

But as an example of the margins effect, EQNX is having 14% revenue growth, but >25% EPS growth due to fixed costs being spread over more sales, and good cost controls. It can happen, but we'll need to monitor the sales/expenses ratios to see if TRIBY can acheive the improved margin dynamic. All 4 now, Scott
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News